YAKUP YÜREKLİ, PERİHAN ÜNAK, Türkan ERTAY, Fazilet Zümrüt MÜFTÜLER BİBER, Emin İlker MEDİNE, Çiğdem ACAR

Radiopharmaceutical model using 99mTc-DMSA to evaluate amifostine protection against cisplatin nephrotoxicity in rats

Çalışmanın amacı sisplatinin neden olduğu nefrotoksisiteye karşı amifostinin koruyucu etkisini bir in vivo radyofarmasötik model kullanarak araştırmaktı. Gereç ve Yöntemler: Erkek Wistar sıçanları her biri 6 hayvandan oluşan 4 gruba ayrıldı: 1) Serum fizyolojik (kontrol); 2) Amifostin (AMI; 200 mg /kg intraperitoneal); 3) Sisplatin (CIS; 5 mg/kg intraperitoneal); 4) Sisplatin artı amifostin (CIS + AMI). Grup 4’te amifostin sisplatinden 30 dakika once enjekte edildi. İlaçlar verildikten sonraki 72. saatte kuyruk veninden plazma BUN ve kreatinin düzeylerini belirlemek amacıyla kan örnekleri alındıktan sonra 7.4 MBq/0.2 ml 99mTc-DMSA enjekte edildi. Radyofarmasötiğin enjeksiyonundan 120 dakika sonra sıçanlar öldürüldü ve böbrekleri çıkarıldı. Her bir doku örneğindeki radyoaktivite RAD 501 tek kanallı analizörü olan bir Cd(Te) dedektörle sayıldı ve her bir böbrekteki aktivite enjekte edilen total aktivite ve organın kitlesine bölünerek bir %ID/gr aktivitesi hesaplandı. Bulgular: Kontrol ve AMI gruplarında %ID/g olarak 99mTc-DMSA uptake’i sırasıyla 8.9938 ± 1.5220 ve 6.4898 ± 1.4091 idi. Sisplatin uygulaması CIS grubunda %ID/g’de anlamlı azalmaya neden oldu (1.5913 ± 0.4566) (p

Sisplatin nefrotoksisitesine karşı amifostinin koruyuculuğunun değerlendirilmesinde 99mTc-DMSA radyofarmasötik modeli

Ob jec ti ve: The aim of our study was to use an in vi vo ra di op har ma ce u ti cal mo del to in ves - ti ga te the cytop ro tec ti ve ef fect of ami fos ti ne aga inst cisp la tin-in du ced nep hro to xi city. Ma te ri al and Met - hods: Ma le Wis tar rats we re di vi ded in to fo ur gro ups of six ani mals each: 1) Sa li ne (con trol); 2) Ami fos ti ne (AMI; 200 mg /kg in tra pe ri to ne ally); 3) Cisp la tin (CIS; 5 mg/kg in tra pe ri to ne ally); 4) Cisp la tin plus ami - fos ti ne (CIS + AMI). Ami fos ti ne was in jec ted 30 mi nu tes be fo re cisp la tin in Gro up 4. 99mTc-DMSA, 7.4 MBq/0.2 ml, was in jec ted thro ugh the ta il ve in 72 ho urs af ter the drug ad mi nis tra ti on. Blo od samp les we - re ob ta i ned for the as says of plas ma cre a ti ni ne and blo od ure a nit ro gen (BUN). Rats we re kil led and the kid neys we re re mo ved by dis sec ti on 120 mi nu tes af ter the in jec ti on of the ra di op har ma ce u ti cal. Ra di o - ac ti vity in each or gan samp le was co un ted using a Cd(Te) de tec tor equ ip ped with a RAD 501 sing lechan nel analy zer and a %ID/g ac ti vity was cal cu la ted by di vi ding the ac ti vity in each kid ney by the to tal ac ti vity in jec ted and the mass of the or gan. Re sults: 99mTc-DMSA up ta ke as %ID/g was 8.9938 ± 1.5220 and 6.4898 ± 1.4091 in the con trol and AMI gro ups res pec ti vely. Cisp la tin ad mi nis tra ti on re sul ted a sig - ni fi cant dec re a se in %ID/g (1.5913 ± 0.4566) (p<0.01). Ami fos ti ne ad mi nis tra ti on 30 mi nu tes be fo re cisp - la tin in jec ti on re sul ted a sig ni fi cant in cre a se in %ID/g (7.3670 ± 2.6090) com pa red to cisp la tin-tre a ted rats (p<0.002). A mar ked in cre a se in plas ma BUN and cre a ti ni ne in di ca ting nep hro to xi city and acu te re nal fa i lu re was ob ser ved in the cisp la tin-tre a ted gro up. Conc lu si on: The re sults sho wed that ami fos ti ne sig - ni fi cantly at te nu a ted cisp la tin-in du ced nep hro to xi city. We conc lu de that this ra di op har ma ce u ti cal mo - del is ab le to de mons tra te cisp la tin nep hro to xi city and ami fos ti ne pro tec ti on aga inst it.

PDF

___

1. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 1993; 27:1519-25.
2. Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 2003;1:47-61.
3. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24:19-38.
4. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17:3333-55.
5. Mahaney Jr FX. Agent designed for war now in doctor’s armamentarium. J Natl Cancer Inst 1990; 82:255-7.
6. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002; 13:181-209.
7. Culy CR, Spencer CM. Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001;61:641-84.
8. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? The Lancet Oncology 2003;4:378-81.
9. Sampson CB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Saf 1993; 8: 280-94.
10. Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med 1994; 21: 348-56.
11. Hladik WB, Nigg KK, Rhodes BA. Drug-induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med 1982; 7:184-218.
12. Lin TH, Khentigan A, Winchell HS. A 99mTcchelate substitute for organoradiomercurial renal agents. J Nucl Med 1974;15:34-5.
13. Enlander D, Weber PM, dos Remedios LV. Renal cortical imaging in 35 patients: superior quality with 99mTc-DMSA. J Nucl Med 1974; 15:743-9.
14. Muller-Suur R, Gutsche HU. Tubular reabsorption of technetium-99m-DMSA. J Nucl Med 1995; 36:1654-8.
15. Provoost, A. P. and M. Van Aken. Renal handling of technetium-99m DMSA in rats with proximal tubular dysfunction. J Nucl Med 1985; 26: 1063-7.
16. van Luyk WH, Ensing GJ, Piers DA. Low renal uptake of 99mTc-DMSA in patients with proximal tubular dysfunction. Eur J Nucl Med 1983;8:404-5.
17. Weichert-Jacobsen KJ, Bannowski A, Küppers F, Loch T, Stöckle M. Direct amifostine effect on renal tubule cells in rats. Cancer Res 1999;59(14):3451-3.
18. Korst AE, van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, van der Vijgh WJ. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 1998;4(2):331-6.
19. Capizzi RL. The preclinical basis for broadspectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur J Cancer 1996; 32A Suppl 4:5- 16.
20. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol 1994; 21 Suppl 11:8-15.
21. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al. Amifostine pretreatment for protection against cyclophosphamide- induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14: 2101-12.
22. Buntzel J. Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998;9:505-9
23. Moretti JL, Rapin JR, Saccavini JC. 2-3 dimerkaptosuccinic acid 2. Renal localization. Int J Nucl Med Biol 1984;11:275-9.
24. Yamada M. Assessment of 99mTc-DMSA renography and uptake compared with creatinine clearance in rats with drug-induced nephrotoxicity--II. Cisplatin-induced nephrotoxicity. Kaku Igaku 1991;28:347-54.
25. Yamada M. Assessment of 99mTc-DMSA renography and uptake compared with creatinine clearance in rats with drug-induced nephrotoxicity--I. Gentamicin-induced nephrotoxicity. Kaku Igaku 1991; 28: 339-45.
26. Anninga JK, Valdes Olmos RA, de Kraker J, van Tinteren H, Hoefnagel CA, van Royen EA. Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer. Eur J Nucl Med 1994;21:658-662.
27. Caglar M, Yaris N, Akyuz C. The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity. Nucl Med Comm 2001; 22:1325-32.
28. Britto DM, Gomes ML, Rodrigues PC, Paula EF, Gutfilen B, Bernardo-Filho MM. Effect of a chemotherapeutic drug on the biodistribution of 99mTc-DTPA in Balb/c mice. J Exp Clin Cancer Res 1998;17:313-316.
29. Gomes ML, de Mattos DM, de Souza Freitas R, Bezerra RJ, Bernardo-Filho M. Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations. Hum Exp Toxicol 2001; 20:193-7.
30. Mattos DM, Gomes ML, Freitas RS, Boasquevisque EM, Cardoso VN, Paula EF, et al. The effect of vincristine on the biodistribution of technetium-99m DTPA, GHA, and DMSA in Balb/c female mice. J Nucl Med Technol 2000; 28:271-4.

Turkish Journal of Nuclear Medicine (. Molecular Imaging and Radionuclide Therapy)-Cover

ISSN: 1304-1495
Yayın Aralığı: Yılda 4 Sayı
Başlangıç: 1992
Yayıncı: Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.